The role of CD44 in disease pathophysiology and targeted treatment

Frontiers in Immunology

Volumn 6, Issue APR, 2015, Pages

  Jordan, Andre R ^a   Racine, Ronny R ^a   Hennig, Martin J P ^a,b   Lokeshwar, Vinata B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CD44; CD44 signaling; Hyaluronic acid; Hyaluronidase

Indexed keywords

BETA DEFENSIN 2; COLLAGEN TYPE 1; COLLAGENASE 3; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HERMES ANTIGEN; HYALURONIC ACID; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MOESIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MYELOID DIFFERENTIATION FACTOR 88; N ACETYLGLUCOSAMINE; PROTEIN KINASE C ALPHA; RANTES; SCATTER FACTOR; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNINDEXED DRUG;

BACTERIAL INFECTION; CANCER THERAPY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); EPITHELIAL MESENCHYMAL TRANSITION; HELICOBACTER INFECTION; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; LUNG DISEASE; LYMPHOCYTE ACTIVATION; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION; WOUND HEALING;

EID: 84934278478     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00182     Document Type: Review

References (134)

1. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol (1994) 6:726-33. doi: 10.1016/0955-0674(94)90100-7
2. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res (1997) 71:241-319. doi:10.1016/S0065-230X(08)60101-3
3. Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, et al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol (2007) 26:58-68. doi:10.1016/j.matbio.2006.08.261
4. Heldin P, Karousou E, Bernert B, Porsch H, Nishitsuka K, Skandalis SS. Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis. Connect Tissue Res (2008) 49:215-8. doi:10.1080/03008200802143323
5. Misra S, Hascall VC, Berger FG, Markwald RR, Ghatak S. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res (2008) 49:219-24. doi:10.1080/03008200802143356
6. Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets (2010) 10:287-306. doi:10.2174/156800910791190193
7. Klingbeil P, Isacke CM. The 'alternative' EMT switch. Breast Cancer Res (2011) 13:313. doi:10.1186/bcr2915
8. Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res (2011) 9:1573-86. doi:10.1158/1541-7786.MCR-11-0156
9. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target (2012) 20:561-73. doi:10.3109/1061186X.2012.702767
10. Neri P, Bahlis NJ. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets (2012) 12:776-96. doi:10.2174/156800912802429337
11. Heldin P, Basu K, Olofsson B, Porsch H, Kozlova I, Kahata K. Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J Biochem (2013) 154:395-408. doi:10.1093/jb/mvt085
12. Nikitovic D, Kouvidi K, Karamanos NK, Tzanakakis GN. The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression. Biomed Res Int (2013) 2013:929531. doi:10.1155/2013/929531
13. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 91:221-64. doi:10.1152/physrev.00052.2009
14. Siegelman MH, Degrendele HC, Estess P. Activation and interaction of CD44 and hyaluronan in immunological systems. J Leukoc Biol (1999) 66:315-21.
15. Hill DR, Rho HK, Kessler SP, Amin R, Homer CR, Mcdonald C, et al. Human milk hyaluronan enhances innate defense of the intestinal epithelium. J Biol Chem (2013) 288:29090-104. doi:10.1074/jbc. M113.468629
16. Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol (1990) 144:7-15.
17. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science (1997) 278:672-5. doi:10.1126/science.278.5338.672
18. Hill DR, Kessler SP, Rho HK, Cowman MK, De La Motte CA. Specific-sized hyaluronan fragments promote expression of human beta-defensin 2 in intestinal epithelium. J Biol Chem (2012) 287:30610-24. doi:10.1074/jbc. M112.356238
19. Gariboldi S, Palazzo M, Zanobbio L, Selleri S, Sommariva M, Sfondrini L, et al. Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. J Immunol (2008) 181:2103-10. doi:10.4049/jimmunol.181.3.2103
20. Dusio GF, Cardani D, Zanobbio L, Mantovani M, Luchini P, Battini L, et al. Stimulation of TLRs by LMW-HA induces self-defense mechanisms in vaginal epithelium. Immunol Cell Biol (2011) 89:630-9. doi:10.1038/icb.2010.140
21. Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H, Golenbock D, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2. J Biol Chem (2007) 282:18265-75. doi:10.1074/jbc. M606352200
22. Yang C, Cao M, Liu H, He Y, Xu J, Du Y, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem (2012) 287:43094-107. doi:10.1074/jbc. M112.349209
23. Sandson J, Hamerman D, Janis R, Rojkind M. Immunologic and chemical similarities between the Streptococcus and human connective tissue. Trans Assoc Am Physicians (1968) 81:249-57.
24. Schrager HM, Alberti S, Cywes C, Dougherty GJ, Wessels MR. Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest (1998) 101:1708-16. doi:10.1172/JCI2121
25. Cywes C, Stamenkovic I, Wessels MR. CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest (2000) 106:995-1002. doi:10.1172/JCI10195
26. Schommer NN, Muto J, Nizet V, Gallo RL. Hyaluronan breakdown contributes to immune defense against group A Streptococcus. J Biol Chem (2014) 289:26914-21. doi:10.1074/jbc. M114.575621
27. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol (2006) 177:1272-81. doi:10.4049/jimmunol.177.2.1272
28. Vachon E, Martin R, Plumb J, Kwok V, Vandivier RW, Glogauer M, et al. CD44 is a phagocytic receptor. Blood (2006) 107:4149-58. doi:10.1182/blood-2005-09-3808
29. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer (2014) 50:1330-44. doi:10.1016/j.ejca.2014.01.029
30. Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology (2008) 134:511-22. doi:10.1053/j.gastro.2007.11.058
31. Khurana SS, Riehl TE, Moore BD, Fassan M, Rugge M, Romero-Gallo J, et al. The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation. J Biol Chem (2013) 288:16085-97. doi:10.1074/jbc. M112.445551
32. Wang Q, Teder P, Judd NP, Noble PW, Doerschuk CM. CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am J Pathol (2002) 161:2219-28. doi:10.1016/S0002-9440(10)64498-7
33. van der Windt GJ, Hoogendijk AJ, De Vos AF, Kerver ME, Florquin S, Van Der Poll T. The role of CD44 in the acute and resolution phase of the host response during pneumococcal pneumonia. Lab Invest (2011) 91:588-97. doi:10.1038/labinvest.2010.206
34. van der Windt GJ, Florquin S, De Vos AF, Van't Veer C, Queiroz KC, Liang J, et al. CD44 deficiency is associated with increased bacterial clearance but enhanced lung inflammation during Gram-negative pneumonia. Am J Pathol (2010) 177:2483-94. doi:10.2353/ajpath.2010.100562
35. Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Pure E, et al. Resolution of lung inflammation by CD44. Science (2002) 296:155-8. doi:10.1126/science.1069659
36. Guo MM, Hildreth JE. HIV acquires functional adhesion receptors from host cells. AIDS Res Hum Retroviruses (1995) 11:1007-13. doi:10.1089/aid.1995.11.1007
37. Bastiani L, Laal S, Kim M, Zolla-Pazner S. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol (1997) 71:3444-50.
38. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol (2000) 74:139-45. doi:10.1128/JVI.74.1.139-145.2000
39. Li P, Fujimoto K, Bourguingnon L, Yukl S, Deeks S, Wong JK. Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells. Immunol Cell Biol (2014) 92:770-80. doi:10.1038/icb.2014.50
40. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 194:895-903. doi:10.1086/507307
41. Abe T, Fukuhara T, Wen X, Ninomiya A, Moriishi K, Maehara Y, et al. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with toll-like receptor 2 and hyaluronan. J Virol (2012) 86:6159-70. doi:10.1128/JVI.06872-11
42. Li Y, Jiang D, Liang J, Meltzer EB, Gray A, Miura R, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med (2011) 208:1459-71. doi:10.1084/jem.20102510
43. Tolg C, Hamilton SR, Nakrieko KA, Kooshesh F, Walton P, Mccarthy JB, et al. Rhamm-/-fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol (2006) 175:1017-28. doi:10.1083/jcb.200511027
44. Ghatak S, Bogatkevich GS, Atnelishvili I, Akter T, Feghali-Bostwick C, Hoffman S, et al. Overexpression of c-Met and CD44v6 receptors contributes to autocrine TGF-beta1 signaling in interstitial lung disease. J Biol Chem (2014) 289:7856-72. doi:10.1074/jbc. M113.505065
45. Evanko SP, Potter-Perigo S, Petty LJ, Workman GA, Wight TN. Hyaluronan controls the deposition of fibronectin and collagen and modulates TGF-beta1 induction of lung myofibroblasts. Matrix Biol (2014). doi:10.1016/j.matbio.2014.12.001
46. Dicker KT, Gurski LA, Pradhan-Bhatt S, Witt RL, Farach-Carson MC, Jia X. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater (2014) 10:1558-70. doi:10.1016/j.actbio.2013.12.019
47. Kikuchi S, Griffin CT, Wang SS, Bissell DM. Role of CD44 in epithelial wound repair: migration of rat hepatic stellate cells utilizes hyaluronic acid and CD44v6. J Biol Chem (2005) 280:15398-404. doi:10.1074/jbc. M414048200
48. Mondalek FG, Fung KM, Yang Q, Wu W, Lu W, Palmer BW, et al. Temporal expression of hyaluronic acid and hyaluronic acid receptors in a porcine small intestinal submucosa-augmented rat bladder regeneration model. World J Urol (2014). doi:10.1007/s00345-014-1403-5
49. Muller J, Gorressen S, Grandoch M, Feldmann K, Kretschmer I, Lehr S, et al. Interleukin-6-dependent phenotypic modulation of cardiac fibroblasts after acute myocardial infarction. Basic Res Cardiol (2014) 109:440. doi:10.1007/s00395-014-0440-y
50. West DC, Shaw DM, Lorenz P, Adzick NS, Longaker MT. Fibrotic healing of adult and late gestation fetal wounds correlates with increased hyaluronidase activity and removal of hyaluronan. Int J Biochem Cell Biol (1997) 29:201-10. doi:10.1016/S1357-2725(96)00133-1
51. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 4:528-39. doi:10.1038/nrc1391
52. Buchanan EP, Longaker MT, Lorenz HP. Fetal skin wound healing. Adv Clin Chem (2009) 48:137-61. doi:10.1016/S0065-2423(09)48006-5
53. Leung A, Crombleholme TM, Keswani SG. Fetal wound healing: implications for minimal scar formation. Curr Opin Pediatr (2012) 24:371-8. doi:10.1097/MOP.0b013e3283535790
54. de la Motte C, Nigro J, Vasanji A, Rho H, Kessler S, Bandyopadhyay S, et al. Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol (2009) 174:2254-64. doi:10.2353/ajpath.2009.080831
55. de la Motte CA, Drazba JA. Viewing hyaluronan: imaging contributes to imagining new roles for this amazing matrix polymer. J Histochem Cytochem (2011) 59:252-7. doi:10.1369/0022155410397760
56. Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: a key molecule in skin aging. Dermatoendocrinol (2012) 4:253-8. doi:10.4161/derm.21923
57. Tolg C, Hamilton SR, Zalinska E, Mcculloch L, Amin R, Akentieva N, et al. A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds. Am J Pathol (2012) 181:1250-70. doi:10.1016/j.ajpath.2012.06.036
58. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol (2007) 23:435-61. doi:10.1146/annurev.cellbio.23.090506.123337
59. Vistejnova L, Safrankova B, Nesporova K, Slavkovsky R, Hermannova M, Hosek P, et al. Low molecular weight hyaluronan mediated CD44 dependent induction of IL-6 and chemokines in human dermal fibroblasts potentiates innate immune response. Cytokine (2014) 70:97-103. doi:10.1016/j.cyto.2014.07.006
60. Tolg C, Mccarthy JB, Yazdani A, Turley EA. Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues. Biomed Res Int (2014) 2014:103923. doi:10.1155/2014/103923
61. Schmitt M, Metzger M, Gradl D, Davidson G, Orian-Rousseau V. CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ (2014) 22(4):677-89. doi:10.1038/cdd.2014.156
62. Wielenga VJ, Van Der Neut R, Offerhaus GJ, Pals ST. CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv Cancer Res (2000) 77:169-87. doi:10.1016/S0065-230X(08)60787-3
63. Wielenga VJ, Van Der Voort R, Taher TE, Smit L, Beuling EA, Van Krimpen C, et al. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am J Pathol (2000) 157:1563-73. doi:10.1016/S0002-9440(10)64793-1
64. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science (2005) 307:1904-9. doi:10.1126/science.1104815
65. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell (2007) 18:76-83. doi:10.1091/mbc. E06-08-0674
66. Hasenauer S, Malinger D, Koschut D, Pace G, Matzke A, von Au A, et al. Internalization of Met requires the co-receptor CD44v6 and its link to ERM proteins. PLoS One (2013) 8:e62357. doi:10.1371/journal.pone.0062357
67. Hao JJ, Liu Y, Kruhlak M, Debell KE, Rellahan BL, Shaw S. Phospholipase C-mediated hydrolysis of PIP2 releases ERM proteins from lymphocyte membrane. J Cell Biol (2009) 184:451-62. doi:10.1083/jcb.200807047
68. Rajasagi M, von Au A, Singh R, Hartmann N, Zoller M, Marhaba R. Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization. J Cell Mol Med (2010) 14:1453-67. doi:10.1111/j.1582-4934.2009.00909.x
69. Zhu R, Wang SC, Sun C, Tao Y, Piao HL, Wang XQ, et al. Hyaluronan-CD44 interaction promotes growth of decidual stromal cells in human first-trimester pregnancy. PLoS One (2013) 8:e74812. doi:10.1371/journal.pone.0074812
70. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res (2014) 123:35-65. doi:10.1016/B978-0-12-800092-2.00002-2
71. Yang MH, Jong SB, Lu CY, Lin YF, Chiang PW, Tyan YC, et al. Assessing the responses of cellular proteins induced by hyaluronic acid-modified surfaces utilizing a mass spectrometry-based profiling system: over-expression of CD36, CD44, CDK9, and PP2A. Analyst (2012) 137:4921-33. doi:10.1039/c2an35368g
72. Goosney DL, Devinney R, Finlay BB. Recruitment of cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic Escherichia coli pedestals. Infect Immun (2001) 69:3315-22. doi:10.1128/IAI.69.5.3315-3322.2001
73. Torre C, Wang SJ, Xia W, Bourguignon LY. Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling. Arch Otolaryngol Head Neck Surg (2010) 136:493-501. doi:10.1001/archoto.2010.25
74. Wang Y, Yago T, Zhang N, Abdisalaam S, Alexandrakis G, Rodgers W, et al. Cytoskeletal regulation of CD44 membrane organization and interactions with E-selectin. J Biol Chem (2014) 289:35159-71. doi:10.1074/jbc. M114.600767
75. Ilangumaran S, Borisch B, Hoessli DC. Signal transduction via CD44: role of plasma membrane microdomains. Leuk Lymphoma (1999) 35:455-69. doi:10.1080/10428199909169610
76. Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology (2011) 141(2076-2087):e2076. doi:10.1053/j.gastro.2011.08.050
77. Hatano H, Shigeishi H, Kudo Y, Higashikawa K, Tobiume K, Takata T, et al. RHAMM/ERK interaction induces proliferative activities of cementifying fibroma cells through a mechanism based on the CD44-EGFR. Lab Invest (2011) 91:379-91. doi:10.1038/labinvest.2010.176
78. Midgley AC, Rogers M, Hallett MB, Clayton A, Bowen T, Phillips AO, et al. Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. J Biol Chem (2013) 288:14824-38. doi:10.1074/jbc. M113.451336
79. Chen L, Bourguignon LY. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer (2014) 13:52. doi:10.1186/1476-4598-13-52
80. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, et al. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res (2010) 70:2613-23. doi:10.1158/0008-5472.CAN-09-3185
81. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 71:4085-95. doi:10.1158/0008-5472.CAN-10-4610
82. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem (2007) 282:16667-80. doi:10.1074/jbc. M702078200
83. Shigeishi H, Biddle A, Gammon L, Emich H, Rodini CO, Gemenetzidis E, et al. Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3beta influenced by CD44 and RHAMM. Stem Cells (2013) 31:2073-83. doi:10.1002/stem.1418
84. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia (2009) 14:29-43. doi:10.1007/s10911-009-9110-3
85. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24-breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest (2009) 89:857-66. doi:10.1038/labinvest.2009.54
86. Wang L, Su W, Liu Z, Zhou M, Chen S, Chen Y, et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials (2012) 33:5107-14. doi:10.1016/j.biomaterials.2012.03.067
87. Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat (2014) 147:39-49. doi:10.1007/s10549-014-3069-5
88. Jiang W, Zhang Y, Kane KT, Collins MA, Simeone DM, Di Magliano MP, et al. CD44 regulates pancreatic cancer invasion through MT1-MMP. Mol Cancer Res (2015) 13:9-15. doi:10.1158/1541-7786.MCR-14-0076
89. Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, Sato H, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J (2002) 21:3949-59. doi:10.1093/emboj/cdf411
90. Kung CI, Chen CY, Yang CC, Lin CY, Chen TH, Wang HS. Enhanced membrane-type 1 matrix metalloproteinase expression by hyaluronan oligosaccharides in breast cancer cells facilitates CD44 cleavage and tumor cell migration. Oncol Rep (2012) 28:1808-14. doi:10.3892/or.2012.1993
91. Yu D, Shin HS, Lee YS, Lee YC. miR-106b modulates cancer stem cell characteristics through TGF-beta/Smad signaling in CD44-positive gastric cancer cells. Lab Invest (2014) 94:1370-81. doi:10.1038/labinvest.2014.125
92. Wang PC, Weng CC, Hou YS, Jian SF, Fang KT, Hou MF, et al. Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells. Int J Mol Sci (2014) 15:3560-79. doi:10.3390/ijms15033560
93. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate (2014) 74:602-17. doi:10.1002/pros.22775
94. Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells (2014) 32:145-56. doi:10.1002/stem.1556
95. Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol (2014) 44:403-11. doi:10.3892/ijo.2013.2195
96. Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, et al. Silibinin inhibits beta-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal (2013) 25:2625-33. doi:10.1016/j.cellsig.2013.08.028
97. Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol (2012) 41:211-8. doi:10.3892/ijo.2012.1453
98. Lee CS, Na K. Photochemically triggered cytosolic drug delivery using pH-responsive hyaluronic acid nanoparticles for light-induced cancer therapy. Biomacromolecules (2014) 15:4228-38. doi:10.1021/bm501258s
99. Garin T, Rubinstein A, Grigoriadis N, Nedvetzki S, Abramsky O, Mizrachi-Koll R, et al. CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J Neurol Sci (2007) 258:17-26. doi:10.1016/j.jns.2007.01.079
100. Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D. DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther (2008) 7:1615-23. doi:10.1158/1535-7163.MCT-07-2383
101. Weiss L, Botero-Anug AM, Hand C, Slavin S, Naor D. CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice. Isr Med Assoc J (2008) 10:20-5.
102. Pilon-Thomas S, Verhaegen M, Kuhn L, Riker A, Mule JJ. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells. Cancer Immunol Immunother (2006) 55:1238-46. doi:10.1007/s00262-005-0104-8
103. Zou L, Song X, Yi T, Li S, Deng H, Chen X, et al. Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer. Cancer Gene Ther (2013) 20:242-50. doi:10.1038/cgt.2013.12
104. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res (2013) 19:6193-204. doi:10.1158/1078-0432.CCR-13-1536
105. Lara MF, Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP, Leake D, Milstone LM, et al. Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. Hum Gene Ther (2012) 23:816-23. doi:10.1089/hum.2011.211
106. Zeng L, Li J, Li J, Zhang Q, Qian C, Wu W, et al. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles. Pancreas (2014) 44(2):250-9. doi:10.1097/MPA.0000000000000241
107. Kim E, Yang J, Kim HO, An Y, Lim EK, Lee G, et al. Hyaluronic acid receptor-targetable imidazolized nanovectors for induction of gastric cancer cell death by RNA interference. Biomaterials (2013) 34:4327-38. doi:10.1016/j.biomaterials.2013.02.006
108. Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials (2013) 34:3489-502. doi:10.1016/j.biomaterials.2013.01.077
109. Wang S, Cao M, Deng X, Xiao X, Yin Z, Hu Q, et al. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Adv Healthc Mater (2015) 4:281-90. doi:10.1002/adhm.201400222
110. Ganesh S, Iyer AK, Gattacceca F, Morrissey DV, Amiji MM. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release (2013) 172:699-706. doi:10.1016/j.jconrel.2013.10.016
111. Almalik A, Day PJ, Tirelli N. HA-coated chitosan nanoparticles for CD44-mediated nucleic acid delivery. Macromol Biosci (2013) 13:1671-80. doi:10.1002/mabi.201300302
112. Yoon HY, Kim HR, Saravanakumar G, Heo R, Chae SY, Um W, et al. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting. J Control Release (2013) 172:653-61. doi:10.1016/j.jconrel.2013.09.008
113. Dalla Pozza E, Lerda C, Costanzo C, Donadelli M, Dando I, Zoratti E, et al. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim Biophys Acta (2013) 1828:1396-404. doi:10.1016/j.bbamem.2013.01.020
114. Yang X, Iyer AK, Singh A, Milane L, Choy E, Hornicek FJ, et al. Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm Res (2014). doi:10.1007/s11095-014-1602-1
115. Thomas RG, Moon M, Lee S, Jeong YY. Paclitaxel loaded hyaluronic acid nanoparticles for targeted cancer therapy: in vitro and in vivo analysis. Int J Biol Macromol (2015) 72:510-8. doi:10.1016/j.ijbiomac.2014.08.054
116. Song S, Qi H, Xu J, Guo P, Chen F, Li F, et al. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm Res (2014) 31:2988-3005. doi:10.1007/s11095-014-1393-4
117. Zhao Y, Zhang T, Duan S, Davies NM, Forrest ML. CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy. Nanomedicine (2014) 10:1221-30. doi:10.1016/j.nano.2014.02.015
118. El-Dakdouki MH, Xia J, Zhu DC, Kavunja H, Grieshaber J, O'Reilly S, et al. Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles. ACS Appl Mater Interfaces (2014) 6:697-705. doi:10.1021/am404946v
119. Crow AR, Yu H, Han D, Lazarus AH. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway. PLoS One (2013) 8:e71882. doi:10.1371/journal.pone.0071882
120. Mott PJ, Lazarus AH. CD44 antibodies and immune thrombocytopenia in the amelioration of murine inflammatory arthritis. PLoS One (2013) 8:e65805. doi:10.1371/journal.pone.0065805
121. Runnels HA, Weber GL, Min J, Kudlacz EM, Zobel JF, Donovan CB, et al. PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases. Adv Ther (2010) 27:168-80. doi:10.1007/s12325-010-0010-0
122. Kodama K, Toda K, Morinaga S, Yamada S, Butte AJ. Anti-CD44 antibody treatment lowers hyperglycemia and improves insulin resistance, adipose inflammation, and hepatic steatosis in diet-induced obese mice. Diabetes (2014) 64(3):867-75. doi:10.2337/db14-0149
123. Kodama K, Horikoshi M, Toda K, Yamada S, Hara K, Irie J, et al. Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc Natl Acad Sci U S A (2012) 109:7049-54. doi:10.1073/pnas.1114513109
124. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A (2013) 110:6127-32. doi:10.1073/pnas.1221841110
125. Vugts DJ, Heuveling DA, Stigter-Van Walsum M, Weigand S, Bergstrom M, Van Dongen GA, et al. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: prelude to phase 1 clinical studies. MAbs (2014) 6:567-75. doi:10.4161/mabs.27415
126. Li L, Hao X, Qin J, Tang W, He F, Smith A, et al. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology (2014) 146:1108-18. doi:10.1053/j.gastro.2013.12.035
127. Sandstrom K, Nestor M, Ekberg T, Engstrom M, Anniko M, Lundqvist H. Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody. Tumour Biol (2008) 29:137-44. doi:10.1159/000143399
128. Sandstrom K, Haylock AK, Spiegelberg D, Qvarnstrom F, Wester K, Nestor M. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio. Int J Oncol (2012) 40:1525-32. doi:10.3892/ijo.2012.1352
129. Chopra A. Humanized anti-CD44v6 monoclonal antibody labeled with IRDye800CW. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda, MD (2004).
130. Vermeulen JF, Van Brussel AS, Adams A, Mali WP, Van Der Wall E, Van Diest PJ, et al. Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study. Mol Imaging Biol (2013) 15:290-8. doi:10.1007/s11307-012-0605-8
131. Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm (2008) 5:474-86. doi:10.1021/mp800024g
132. Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol (2008) 44:823-9. doi:10.1016/j.oraloncology.2007.10.009
133. Qian C, Wang Y, Chen Y, Zeng L, Zhang Q, Shuai X, et al. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials (2013) 34:6175-84. doi:10.1016/j.biomaterials.2013.04.056
134. Somasunderam A, Thiviyanathan V, Tanaka T, Li X, Neerathilingam M, Lokesh GL, et al. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry (2010) 49:9106-12. doi:10.1021/bi1009503